The FDA approved sotorasib and panitumumab for metastatic colorectal cancer with the KRAS G12C mutation. The U.S. Food and Drug Administration (FDA) approved sotorasib (Lumakras) in combination with panitumumab (Vectibix) for the treatment of...
Acalabrutinib was granted traditional approval as a monotherapy for previously treated MCL and as part of a combination for untreated MCL. The U.S. Food and Drug Administration (FDA) has granted traditional approval to acalabrutinib...
The FDA approved nivolumab and hyaluronidase-nvhy as an injectable therapy for multiple tumor types. The U.S. Food and Drug Administration (FDA) has approved nivolumab and hyaluronidase-nvhy (Opdivo Qvantig) for subcutaneous (under the skin) injection...
The FDA approved the kinase inhibitors encorafenib and cetuximab plus chemotherapy for the treatment of certain colorectal cancers. The U.S. Food and Drug Administration (FDA) has granted accelerated approval to encorafenib (Braftovi), in combination...
The FDA approved the mesenchymal stromal cell therapy remestemcel-L-rknd for some pediatric patients as young as 2 months. The U.S. Food and Drug Administration (FDA) has approved remestemcel-L-rknd (Ryoncil) for the treatment of...
The FDA approved ensartinib for certain patients with locally advanced or metastatic non-small cell lung cancer. The U.S. Food and Drug Administration (FDA) has approved ensartinib (Ensacove) for adults with non-small cell lung cancer...
The FDA approved cosibelimab-ipdl for certain skin cancers that cannot be treated with surgery or radiation. The U.S. Food and Drug Administration (FDA) has approved cosibelimab-ipdl (Unloxcyt) for the treatment of adult patients with...
The FDA approved durvalumab for some patients with previously treated limited-stage small cell lung cancer. The U.S. Food and Drug Administration (FDA) has approved durvalumab (Imfinzi) for the treatment of adults with limited-stage...
The FDA approved the targeted therapy zenocutuzumab-zbco for certain patients with lung or pancreatic cancer. The U.S. Food and Drug Administration (FDA) has granted accelerated approval to zenocutuzumab-zbco (Bizengri) for the treatment of adult...
The FDA granted accelerated approval to the first-in-class HER2-directed bispecific antibody zanidatamab-hrii. The U.S. Food and Drug Administration (FDA) has granted accelerated approval to zanidatamab-hrii (Ziihera) for previously treated, unresectable or metastatic human epidermal...
AACR Fellow Lewis C. Cantley, PhD, leads a national effort targeting triple-negative breast cancer and ovarian cancer with a novel drug combination.
Learn More